<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0872-671X</journal-id>
<journal-title><![CDATA[Medicina Interna]]></journal-title>
<abbrev-journal-title><![CDATA[Medicina Interna]]></abbrev-journal-title>
<issn>0872-671X</issn>
<publisher>
<publisher-name><![CDATA[Sociedade Portuguesa de Medicina Interna]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0872-671X2023000400003</article-id>
<article-id pub-id-type="doi">10.24950/rspmi.1602</article-id>
<title-group>
<article-title xml:lang="pt"><![CDATA[Hipocoagulação em Doentes com Fibrilhação Auricular e Internados por AVC Hemorrágico]]></article-title>
<article-title xml:lang="en"><![CDATA[Hipocoagulation in Patients with Atrial Fibrillation and Admitted for Hemorrhagic Stroke]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Santos]]></surname>
<given-names><![CDATA[Maria Beatriz]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodrigues]]></surname>
<given-names><![CDATA[Alexandra]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[Patrícia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Nunes]]></surname>
<given-names><![CDATA[Ana Paiva]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital de Santo Espírito da Ilha Terceira Serviço de Medicina Interna ]]></institution>
<addr-line><![CDATA[ Açores]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Central do Funchal Neuroradiology Unit ]]></institution>
<addr-line><![CDATA[Funchal ]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Centro Hospitalar Universitário de Lisboa Central Neuroradiology department ]]></institution>
<addr-line><![CDATA[Lisboa ]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Centro Hospitalar Universitário de Lisboa Central Hospital de São José Unidade Cerebro-Vascular]]></institution>
<addr-line><![CDATA[Lisboa ]]></addr-line>
<country>Portugal</country>
</aff>
<pub-date pub-type="pub">
<day>30</day>
<month>12</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>30</day>
<month>12</month>
<year>2023</year>
</pub-date>
<volume>30</volume>
<numero>4</numero>
<fpage>3</fpage>
<lpage>8</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_arttext&amp;pid=S0872-671X2023000400003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_abstract&amp;pid=S0872-671X2023000400003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_pdf&amp;pid=S0872-671X2023000400003&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo  Introdução:  A estratégia de prevenção secundária em doentes com acidente vascular cerebral hemorrágico (AVCh) e fibrilhação auricular (FA) é um dilema clínico. O objetivo dos autores foi avaliar a introdução ou manutenção de terapêutica hipocoagulante em doentes com FA e internados por AVCh.  Métodos:  Análise descritiva dos doentes internados por AVCh de 2009 a 2021. Foi feita a colheita de dados pela consulta dos processos e analisados dados demográficos, clínicos, imagiológicos e a terapêutica prévia e após alta. Realizou-se uma análise comparativa da terapêutica hipo-coagulante entre anticoagulantes orais diretos (DOAC) e antagonistas da vitamina K (AVK).  Resultados:  Um total de 28 doentes (22 do género masculino; mediana de idade de 75 anos) foram incluídos no estudo, dos quais 19 eram hipocoagulados previamente. Destes, oito (re)iniciaram a hipocoagulação após a alta. Verificou-se o óbito em 19 doentes, dos quais 17 pertenciam ao grupo sem hipocoagulação após alta e destes, cinco óbitos foram verificados no primeiro mês após o AVCh.  Conclusão:  A maioria dos doentes não (re)iniciou hipo-coagulação após AVCh, apesar de serem um grupo de alto risco para novos eventos cerebrovasculares, o que torna a discussão sobre este tema ainda mais relevante. Assistiu-se a uma mudança no padrão de prescrição de AVK para DOAC, comparando os dois períodos em análise.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction:  The stroke prevention strategy in patients with intracerebral hemorrhage (ICH) and atrial fibrillation (AF) is a clinical dilemma. The aim of this study was to evaluate the management of anticoagulation therapy in patients with AF and admitted with ICH.  Methods:  We performed a descriptive analysis of patients admitted for ICH from 2009 to 2021. Data collection was carried out by consulting the processes and analyzing demographic, clinical and imaging data, and prior and post--discharge therapy. A comparative analysis of outcomes of anticoagulant therapy was performed between direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs).  Results:  A total of 28 patients (22 male patients; median age 75 years) were included in the study, of which 19 were previously on anticoagulation therapy. Only eight (re)started anticoagulation after discharge. There were 19 deaths, of which 17 were in the group without post-discharge anticoagulation; of those, five occurred in the first month after ICH.  Conclusion:  Most patients did not (re)initiate anticoagulation after ICH, despite being a high-risk group for new cerebrovascular events, which makes the discussion on this topic even more relevant. There was a change in the prescription pattern from VKAs to DOACs, comparing the two periods analyzed.]]></p></abstract>
<kwd-group>
<kwd lng="pt"><![CDATA[Acidente Vascular Cerebral Hemorrágico]]></kwd>
<kwd lng="pt"><![CDATA[Anticoagulantes]]></kwd>
<kwd lng="pt"><![CDATA[Fibrilhação Auricular.]]></kwd>
<kwd lng="en"><![CDATA[Anticoagulants]]></kwd>
<kwd lng="en"><![CDATA[Atrial Fibrillation]]></kwd>
<kwd lng="en"><![CDATA[Hemorrhagic Stroke.]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Klijn]]></surname>
<given-names><![CDATA[CJM]]></given-names>
</name>
<name>
<surname><![CDATA[Paciaroni]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Berge]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Korompoki]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Kõrv]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lal]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anti-thrombotic treatment for secondary prevention of stroke and other throm-boembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation A European Stroke Organisation guideline]]></article-title>
<source><![CDATA[Eur Stroke J]]></source>
<year>2019</year>
<volume>4</volume>
<page-range>198-223</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sargento-Freitas]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Koehler]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Isidoro]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Mendonça]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Machado]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fibrilhação Auricular na Doença Cerebrovascular A Perspectiva Neu-rológica Nacional]]></article-title>
<source><![CDATA[Acta Med Port]]></source>
<year>2013</year>
<volume>26</volume>
<page-range>86-92</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arnett]]></surname>
<given-names><![CDATA[DK]]></given-names>
</name>
<name>
<surname><![CDATA[Blumenthal]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Albert]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Buroker]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Goldberger]]></surname>
<given-names><![CDATA[ZD]]></given-names>
</name>
<name>
<surname><![CDATA[Hahn]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease Executive Summary: A Report of the American College of Cardio-logy/American Heart Association Task Force on Clinical Practice Guidelines]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2019</year>
<volume>74</volume>
<page-range>1376-414</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Greenberg]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Ziai]]></surname>
<given-names><![CDATA[WC]]></given-names>
</name>
<name>
<surname><![CDATA[Cordonnier]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Dowlatshahi]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Francis]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Golds-tein]]></surname>
<given-names><![CDATA[JN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2022 Guideline for the Management of Patients With Spon-taneous Intracerebral Hemorrhage A Guideline From the American Heart Association/American Stroke Association]]></article-title>
<source><![CDATA[Stroke]]></source>
<year>2022</year>
<volume>53</volume>
<page-range>e282-361</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[INFARMED]]></surname>
<given-names><![CDATA[IP]]></given-names>
</name>
<name>
<surname><![CDATA[Correia]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Costa]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Caldeira]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Anticoagulantes Orais - Utili-zação e Despesa]]></source>
<year>2019</year>
<publisher-loc><![CDATA[Lisboa ]]></publisher-loc>
<publisher-name><![CDATA[Infarmed]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nielsen]]></surname>
<given-names><![CDATA[PB]]></given-names>
</name>
<name>
<surname><![CDATA[Larsen]]></surname>
<given-names><![CDATA[TB]]></given-names>
</name>
<name>
<surname><![CDATA[Gorst-Rasmussen]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Skjøth]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Rasmussen]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Lip]]></surname>
<given-names><![CDATA[GY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intracranial haemorrhage and subsequent ischemic stroke in patients with atrial fibrillation A nationwide cohort study]]></article-title>
<source><![CDATA[Chest]]></source>
<year>2015</year>
<volume>147</volume>
<page-range>1651-8</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nielsen]]></surname>
<given-names><![CDATA[PB]]></given-names>
</name>
<name>
<surname><![CDATA[Melgaard]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Overvad]]></surname>
<given-names><![CDATA[TF]]></given-names>
</name>
<name>
<surname><![CDATA[Jensen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Larsen]]></surname>
<given-names><![CDATA[TB]]></given-names>
</name>
<name>
<surname><![CDATA[Lip]]></surname>
<given-names><![CDATA[GY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk of Cerebrovascular Events in Intracerebral Hemorrhage Survivors With Atrial Fibrillation A Nationwide Cohort Study]]></article-title>
<source><![CDATA[Stroke]]></source>
<year>2022</year>
<volume>53</volume>
<page-range>2559-68</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Jia]]></surname>
<given-names><![CDATA[WB]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[LY]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[TZ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[1/2SH A Simple, Accurate, and Reliable Method of Calculating the Hematoma Volume of Spontaneous Intracerebral Hemorrhage]]></article-title>
<source><![CDATA[Stroke]]></source>
<year>2020</year>
<volume>51</volume>
<page-range>193-201</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ruff]]></surname>
<given-names><![CDATA[CT]]></given-names>
</name>
<name>
<surname><![CDATA[Giugliano]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
<name>
<surname><![CDATA[Braunwald]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Hoffman]]></surname>
<given-names><![CDATA[EB]]></given-names>
</name>
<name>
<surname><![CDATA[Deenadayalu]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Ezekowitz]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation a meta-analy-sis of randomised trials]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2014</year>
<volume>383</volume>
<page-range>955-62</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
